Assess whether scientific advice should be sought before the next trial

SITUATION The working file is CMC comparability package for a site change after a competitor label that just got a narrower indication. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in CMC comparability package for a site change for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT. 4. CMC comparability package for a site change is missing the fact clinical-development physician needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a competitor label that just got a narrower indication. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a competitor label that just got a narrower indication and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.